Abstract:BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease of unknown cause, with limited therapeutic options and an urgent need to develop new treatment methods. However, there is still a lack of suitable inhaled drugs for the treatment of IPF due to non-specific side effects, inability to cross the pulmonary barrier, and inadequate management of heterogeneity. In this study, we hypothesized that tetrandrine liposomes (TET-LIPs) delivered by inhalation might have a direct targeting effect on lung tissue, effectively treat IPF and limit its adverse side effects on other organs.MethodsMorphology, particle size, zeta potential, and in vitro dissolution studies of the prepared TET-LIPs were performed. Blood aspartate aminotransferase (AST), alanine aminotransferase (ALT), Urea nitrogen (BUN), creatinine (Cr) were measured to determine the liver and renal function. Bleomycin-induced mice model of IPF was used to evaluate the in vivo pharmacodynamics of TET-LIPs. The levels of hydroxyproline, tumor necrosis factor (TNF-α), and transforming growth factor (TGF-β1) were examined by enzyme-linked immunosorbent assay (ELISA). Finally, alveolar lavage fluid lipid profiles were obtained by using ultra-performance liquid chromatography combined with quadrupole-Exactive Orbitrap mass spectrometry (UPLC-Q-Exactive Orbitrap MS).ResultsInhaled TET-LIPs significantly inhibited the progression of bleomycin-induced acute inflammation and pulmonary fibrosis in lung tissue. Furthermore, delivering the drug locally to the lungs showed little accumulation in the liver and kidneys after long-term inhalation and had a favorable safety profile. Interestingly, we observed a relationship between inhaled TET-LIPs and increased levels of triglycerides (TG), fatty acids (FA) while decreased levels of lysophosphatidylcholine (LPC) in BALF.ConclusionsOverall, as TET-LIPs were safe and well-tolerated in the BLM-induced mice model, tetrandrine encapsulation in liposomes could be an effective method for locally delivering to patients with IPF. Simultaneously, our findings revealed that various lipid metabolic disorders were linked to the early inflammatory phase of the fibrosis process, and the regulation of lipid metabolism may be one of the mechanisms to improve pulmonary fibrosis using TET-LIPs.

Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge

Inhalation of Itraconazole Mitigates Bleomycin-Induced Lung Fibrosis Via Regulating SPP1 and C3 Signaling Pathway Pivotal in the Interaction Between Phagocytic Macrophages and Diseased Fibroblasts

Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice

Nebulized inhalation of nintedanib-loaded biomimetic nano-liposomes attenuated bleomycin-induced interstitial lung fibrosis in mice

Pulmonary fibroblast-specific delivery of siRNA exploiting exosomes-based nanoscaffolds for IPF treatment

Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy

Anti-HSP47 siRNA lipid nanoparticle ND-L02-s0201 reverses interstitial pulmonary fibrosis in preclinical rat models

Traditional Chinese medicine inspired dual-drugs loaded inhalable nano-therapeutics alleviated idiopathic pulmonary fibrosis by targeting early inflammation and late fibrosis

Inhaled nintedanib nanoparticles for enhanced efficacy in idiopathic pulmonary fibrosis (IPF) treatment – Evidence in disease-relevant in-vitro models

Inhaled Nanoparticles for Treating Idiopathic Pulmonary Fibrosis by Inhibiting Honeycomb Cyst and Alveoli Interstitium Remodeling

Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy

Inhalation of tetrandrine liposomes for the treatment of bleomycin induced idiopathic pulmonary fibrosis

Tanshinone IIA Loaded Inhaled Polymer Nanoparticles Alleviate Established Pulmonary Fibrosis

Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro

Dual Barrier‐Penetrating Inhaled Nanoparticles for Enhanced Idiopathic Pulmonary Fibrosis Therapy

Double Braking Effects of Nanomedicine on Mitochondrial Permeability Transition Pore for Treating Idiopathic Pulmonary Fibrosis

Targeted Dual Small Interfering Ribonucleic Acid Delivery Via Non-Viral Polymeric Vectors for Pulmonary Fibrosis Therapy

Relaxin-Loaded Inhaled Porous Microspheres Inhibit Idiopathic Pulmonary Fibrosis and Improve Pulmonary Function Post-Bleomycin Challenges

Modulating Fibrotic Mechanical Microenvironment for Idiopathic Pulmonary Fibrosis Therapy

Targeting IL‐11 to reduce fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension‐associated lung fibrosis

Treatment of acute lung injury and early- and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes